Posts

http://norml.org/news/2015/02/05/portland-norml-responds-to-olcc-s-first-meeting-on-implementation-of-measure-91-marijuana-legalization

Press release info feb

S&P 500 2,037 +15.99 +0.79% PRESS RELEASE Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) By Published: Feb 2, 2015 8:03 a.m. ET SHARE   CORAL GABLES, Fla., Feb 02, 2015 (GLOBE NEWSWIRE via COMTEX) -- Catalyst Pharmaceutical Partners, Inc. CPRX, +0.00% (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse™ for the treatment of LEMS. Based on this meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse™ for LEMS. The Company plans to complete a full NDA submission during the 3rd quarter of 2015. Catalyst will confirm the overall regulatory path for

New test news oct 8.

http://m.bizjournals.com/southflorida/news/2014/10/06/catalyst-pharma-to-hire-25-people-after-successful.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+industry_6+%28Industry+Health+Care%29&r=full

News oct 8tt

http://money.cnn.com/news/newsfeeds/articles/globenewswire/10101677.htm
http://mobile.reuters.com/article/idUSL3N0RU5QS20140929?irpc=932
http://www.bidnessetc.com/26483-catalyst-surges-on-positive-trial-results/
http://globenewswire.com/news-release/2014/09/29/669185/10100382/en/Catalyst-Pharmaceuticals-Announces-Positive-Top-Line-Phase-3-Data-From-Pivotal-Firdapse-Clinical-Trial-in-Patients-With-Lambert-Eaton-Myasthenic-Syndrome-LEMS.html